New Times,
New Thinking.

  1. Politics
23 March 2015

Jeremy Paxman loves David Cameron – but Team Miliband aren’t worried

Jeremy Paxman's latest comments about the state of British politics will chill Labour partisans - but Team Miliband aren't worried.

By Stephen Bush

The election is “running the Tories’ way”, the leaders he admires are David Cameron, William Hague and Philip Hammond. David Miliband’s “very accomplished”, while Ed Miliband “is alright”. He was asked to be the Conservative candidate in Kensington and Chelsea.

Meet Jeremy Paxman, the man who’s moderating that first debate between Ed Miliband and David Cameron. It’s put the wind up some in Labour;  many already feel that they ended up with a bad deal in the debates, without that right to take on the Prime Minister directly, plus the risky battle with the also-ran debaters. But others are more relaxed; they point out that the veteran anchor hasn’t let his own politics get in the way of roughing up Tories in the past. A senior Labour source says that Paxman’s “real challenge will be holding to account David Cameron, who has been running scared from a head-to-head debate with Ed Miliband and running scared from the public throughout this process.”

Select and enter your email address Your weekly guide to the best writing on ideas, politics, books and culture every Saturday. The best way to sign up for The Saturday Read is via saturdayread.substack.com The New Statesman's quick and essential guide to the news and politics of the day. The best way to sign up for Morning Call is via morningcall.substack.com
Visit our privacy Policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications.
THANK YOU

Content from our partners
Unlocking investment in UK life sciences through manufacturing
Data defines a new era for fundraising
A prescription for success: improving the UK's access to new medicines